This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–2406.
Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur J Surg Oncol. 2018;44:1619–1623.
Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782–794.
Golan T, Barenboim A, Lahat G, et al. Increased rate of complete pathological response following neoadjuvant FOLFIRINOX in BRCA mutation carriers with borderline resectable pancreatic cancer. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08469-8.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Golan, T., Barenboim, A. & Lubezky, N. ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy. Ann Surg Oncol 27, 3971–3972 (2020). https://doi.org/10.1245/s10434-020-08495-6